PD03-02 PHASE 3 RESULTS OF VICINIUM IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000823.02
Abstract: INTRODUCTION AND OBJECTIVE:Alternatives to radical cystectomy (RC) are critically needed for the treatment of high-risk BCG-unresponsive NMIBC. Vicinium is a recombinant fusion protein comprised of... read more here.
Keywords: phase results; bcg unresponsive; results vicinium; vicinium bcg ... See more keywords
PD12-01 ONCOFID-P-B FOR THE TREATMENT OF BCG UNRESPONSIVE CARCINOMA IN SITU (CIS) OF BLADDER
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000846.01
Abstract: INTRODUCTION AND OBJECTIVE:There is an unmet clinical need for new drugs able to delay or avoid cystectomy in patients with CIS unresponsive to BCG. Oncofid - P-B, a new drug that originates from t... read more here.
Keywords: pd12 oncofid; bcg unresponsive; unresponsive carcinoma; treatment bcg ... See more keywords
Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000001515
Abstract: PURPOSE Patients with BCG-unresponsive carcinoma in situ (CIS) are treated with radical cystectomy (RCx) or salvage intravesical chemotherapy (SIC). Recently, pembrolizumab was approved for BCG-unresponsive CIS. MATERIALS AND METHODS We used a decision-analytic Markov model… read more here.
Keywords: bcg unresponsive; pembrolizumab; cost effective; rcx ... See more keywords
Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Current Opinion in Urology"
DOI: 10.1097/mou.0000000000000846
Abstract: PURPOSE OF REVIEW A number of promising therapies for Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer (NMIBC) are in the pipeline. In this review, we discuss the history of immunotherapy for the treatment of… read more here.
Keywords: bcg unresponsive; cancer; calmette guerin; guerin bcg ... See more keywords
Contemporary outcomes of bladder carcinoma in situ treated with an adequate BCG immunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "BJU international"
DOI: 10.1111/bju.15567
Abstract: OBJECTIVE To assess whether bacillus Calmette-Guérin (BCG) responsiveness after initiation of an adequate BCG treatment (at least five of six instillations of induction and at least two of three instillations of maintenance) impacts oncological outcomes… read more here.
Keywords: bcg immunotherapy; adequate bcg; bcg unresponsive; months iqr ... See more keywords
Multi-country clinical practice patterns, including use of biomarkers, among physicians’ treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
Sign Up to like & getrecommendations! Published in 2022 at "BMC Urology"
DOI: 10.1186/s12894-022-00959-z
Abstract: Background Intravesical bacillus Calmette-Guérin (BCG) fails in a considerable proportion of non-muscle invasive bladder cancer (NMIBC) patients despite treatment per recommended protocol. This real-world study aimed to understand the current patterns of treatment and disease… read more here.
Keywords: bcg unresponsive; treatment; bladder; bcg ... See more keywords